Moises Diago

Summary

Country: Spain

Publications

  1. doi request reprint Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin
    Moises Diago
    Hepatology Section, Hospital General de Valencia, Valencia, Spain
    Hepatology 51:1897-903. 2010
  2. ncbi request reprint [Chronic hepatitis C: initial treatment in patients without previous treatment]
    M Diago
    Sección de Hepatología Servicio de Aparato Digestivo Hospital General Universitario Valencia Spain
    Gastroenterol Hepatol 25:347-55. 2002
  3. ncbi request reprint [Does antiviral therapy improve the clinical course of cirrhosis due to hepatitis C virus infection?]
    Moises Diago
    Servicio de Digestivo, Seccion de Hepatologia, Consorcio Hospital General Universitario, Valencia, Spain
    Gastroenterol Hepatol 30:85-92. 2007
  4. ncbi request reprint Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate
    M Diago
    Hospital General de Valencia, Valencia, Spain
    Aliment Pharmacol Ther 25:899-906. 2007
  5. pmc Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
    M Diago
    Section of Hepatology, University General Hospital, Valencia, Spain
    Gut 55:374-9. 2006
  6. ncbi request reprint Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients
    M Diago
    Hepatology Section, Hospital General de Valencia, Valencia, Spain
    Aliment Pharmacol Ther 26:1131-8. 2007
  7. ncbi request reprint [Alternative treatments for patients with chronic C hepatitis who did not respond previous treatments]
    Moises Diago
    Jefe de la Sección de Hepatología, Hospital General de Valencia, Valencia, Espana
    Rev Gastroenterol Mex 70:458-64. 2005
  8. ncbi request reprint Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon
    M Diago
    Hepatology Section, Service of Digestive Diseases, Hospital General Universitario, Valencia, Spain
    Rev Esp Enferm Dig 93:353-63. 2001
  9. ncbi request reprint Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C
    M Diago
    Hospital General Universitario, Valencia, Spain
    J Med Virol 64:460-5. 2001
  10. ncbi request reprint Epidemiological, biological and histological characterization of patients with indeterminate third-generation recombinant immunoblot assay antibody results for hepatitis C virus
    M Rios
    Hepatology Section, Service of Digestive Diseases, University General Hospital, Valencia, Spain
    J Viral Hepat 13:177-81. 2006

Detail Information

Publications11

  1. doi request reprint Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin
    Moises Diago
    Hepatology Section, Hospital General de Valencia, Valencia, Spain
    Hepatology 51:1897-903. 2010
    ..Significant pretreatment predictors of SVR included assignment to 24 weeks of treatment (P = 0.0006), absence of advanced fibrosis on liver biopsy (P = 0.0032), lower HCV RNA level (P = 0.0017), and lower body weight (P < 0.0001)...
  2. ncbi request reprint [Chronic hepatitis C: initial treatment in patients without previous treatment]
    M Diago
    Sección de Hepatología Servicio de Aparato Digestivo Hospital General Universitario Valencia Spain
    Gastroenterol Hepatol 25:347-55. 2002
  3. ncbi request reprint [Does antiviral therapy improve the clinical course of cirrhosis due to hepatitis C virus infection?]
    Moises Diago
    Servicio de Digestivo, Seccion de Hepatologia, Consorcio Hospital General Universitario, Valencia, Spain
    Gastroenterol Hepatol 30:85-92. 2007
    ..Preliminary data indicate that patients with cirrhosis treated with interferon as maintenance therapy show less progression than those treated with colchicine...
  4. ncbi request reprint Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate
    M Diago
    Hospital General de Valencia, Valencia, Spain
    Aliment Pharmacol Ther 25:899-906. 2007
    ..Aim: To assess early virological response and its clinical utility in predicting an sustained virological response in patients suffering from chronic hepatitis C genotype 1 in routine clinical practice in Spain...
  5. pmc Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
    M Diago
    Section of Hepatology, University General Hospital, Valencia, Spain
    Gut 55:374-9. 2006
    ..Increased serum and intrahepatic interferon gamma inducible protein 10 (IP-10) levels in patients with chronic hepatitis C (CHC) have been described...
  6. ncbi request reprint Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients
    M Diago
    Hepatology Section, Hospital General de Valencia, Valencia, Spain
    Aliment Pharmacol Ther 26:1131-8. 2007
    ..Patients infected with hepatitis C virus genotype 1 who are true non-responders to previous therapy suffer from a very difficult-to-cure disease. New approaches to treatment are necessary...
  7. ncbi request reprint [Alternative treatments for patients with chronic C hepatitis who did not respond previous treatments]
    Moises Diago
    Jefe de la Sección de Hepatología, Hospital General de Valencia, Valencia, Espana
    Rev Gastroenterol Mex 70:458-64. 2005
    ..All of these measures not always eradicate HCV, but do slow fibrosis and its complications: liver failure, portal hypertension and hepatocarcinoma...
  8. ncbi request reprint Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon
    M Diago
    Hepatology Section, Service of Digestive Diseases, Hospital General Universitario, Valencia, Spain
    Rev Esp Enferm Dig 93:353-63. 2001
    ..8% of patients (26/77). CONCLUSIONS: Combined IFN-RIB therapy for 12 months in CHC patients without SR to IFN obtains a long-term SR of 22.1%, this rate being higher in relapsers to prior IFN therapy (64.3% in R versus 12.7% in NR)...
  9. ncbi request reprint Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C
    M Diago
    Hospital General Universitario, Valencia, Spain
    J Med Virol 64:460-5. 2001
    ..c. induction with 10 MU IFNalpha-n1 followed by intermittent or continuous maintenance therapy for 1 year does not improve the results achieved with the standard 1-year IFNalpha course in the treatment of chronic hepatitis C patients...
  10. ncbi request reprint Epidemiological, biological and histological characterization of patients with indeterminate third-generation recombinant immunoblot assay antibody results for hepatitis C virus
    M Rios
    Hepatology Section, Service of Digestive Diseases, University General Hospital, Valencia, Spain
    J Viral Hepat 13:177-81. 2006
    ....
  11. ncbi request reprint [Prevalence of anti-hepatitis A in patients with chronic liver disease]
    M Diago
    Servicio de Digestivo, Hospital General Universitario, Valencia
    Gastroenterol Hepatol 21:324-6. 1998
    ..Due to previous cost-benefit studies and the high prevalence found, the determination of anti-HAV in patients with chronic viral liver diseases prior to vaccination against HAV is recommended...